Background: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice.
Methods/results: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae.
Conclusion: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, multiple sclerosis, Immunosuppression, Alemtuzumab,
【저자키워드】 COVID-19, SARS-CoV-2, multiple sclerosis, Immunosuppression, Alemtuzumab,